JP2004532877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004532877A5 JP2004532877A5 JP2003500091A JP2003500091A JP2004532877A5 JP 2004532877 A5 JP2004532877 A5 JP 2004532877A5 JP 2003500091 A JP2003500091 A JP 2003500091A JP 2003500091 A JP2003500091 A JP 2003500091A JP 2004532877 A5 JP2004532877 A5 JP 2004532877A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- prevention
- treatment
- disorder
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 4
- 230000006735 deficit Effects 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 206010057852 Nicotine dependence Diseases 0.000 claims 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000003935 attention Effects 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000028683 bipolar I disease Diseases 0.000 claims 2
- 230000001713 cholinergic effect Effects 0.000 claims 2
- 230000007278 cognition impairment Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000005586 smoking cessation Effects 0.000 claims 2
- 210000000225 synapse Anatomy 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- UMULYXKQASVZSU-TYJDENFWSA-N C1OC=CC1c(cn1)cc(C2)c1O[C@@]21C(CC2)CCN2C1 Chemical compound C1OC=CC1c(cn1)cc(C2)c1O[C@@]21C(CC2)CCN2C1 UMULYXKQASVZSU-TYJDENFWSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29520601P | 2001-06-01 | 2001-06-01 | |
| PCT/SE2002/001031 WO2002096912A1 (en) | 2001-06-01 | 2002-05-29 | Novel ligand for nicotinic acetylcholine receptors useful in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004532877A JP2004532877A (ja) | 2004-10-28 |
| JP2004532877A5 true JP2004532877A5 (enExample) | 2006-01-05 |
Family
ID=23136711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003500091A Pending JP2004532877A (ja) | 2001-06-01 | 2002-05-29 | 治療に有効なニコチン性アセチルコリン受容体に対する新規なリガンド |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1397366B1 (enExample) |
| JP (1) | JP2004532877A (enExample) |
| KR (1) | KR20040003021A (enExample) |
| CN (1) | CN1294136C (enExample) |
| AT (1) | ATE353332T1 (enExample) |
| BR (1) | BR0210075A (enExample) |
| CA (1) | CA2455341A1 (enExample) |
| DE (1) | DE60218032T2 (enExample) |
| DK (1) | DK1397366T3 (enExample) |
| ES (1) | ES2280538T3 (enExample) |
| IL (1) | IL158735A0 (enExample) |
| MX (1) | MXPA03010996A (enExample) |
| NO (1) | NO20035333D0 (enExample) |
| NZ (1) | NZ529426A (enExample) |
| PT (1) | PT1397366E (enExample) |
| SI (1) | SI1397366T1 (enExample) |
| WO (1) | WO2002096912A1 (enExample) |
| ZA (1) | ZA200308779B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| BR0309342A (pt) | 2002-04-18 | 2005-02-15 | Astrazeneca Ab | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas |
| JP4523775B2 (ja) | 2002-04-18 | 2010-08-11 | アストラゼネカ・アクチエボラーグ | 複素環化合物 |
| BR0309343A (pt) * | 2002-04-18 | 2005-02-15 | Astrazeneca Ab | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas |
| JP4855264B2 (ja) * | 2003-10-21 | 2012-01-18 | アストラゼネカ・アクチエボラーグ | スピロフロピリジンアリール誘導体 |
| TW200813067A (en) * | 2006-05-17 | 2008-03-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| CA2728675A1 (en) | 2008-06-20 | 2009-12-23 | Astrazeneca Ab | Dibenzothiazepine derivatives and use thereof |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| TWI519532B (zh) | 2010-05-17 | 2016-02-01 | 艾維沃製藥公司 | （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體 |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| RU2017136693A (ru) | 2012-05-08 | 2019-02-08 | Форум Фармасьютикалз, Инк. | Способы поддержания, лечения или улучшения когнитивной функции |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| US9593106B2 (en) | 2013-02-07 | 2017-03-14 | Heptares Therapeutics Limited | Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists |
| JP6401254B2 (ja) | 2013-06-21 | 2018-10-10 | 武田薬品工業株式会社 | プロキネシチン受容体のモジュレータとしての１−スルホニルピペリジン誘導体 |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
| GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
| GB202414197D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414193D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002500652A (ja) * | 1997-05-30 | 2002-01-08 | ニューロサーアチ・アクティーゼルスカブ | スピロ−キヌクリジン誘導体、その製造方法及びその使用方法 |
| AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
-
2002
- 2002-05-29 WO PCT/SE2002/001031 patent/WO2002096912A1/en not_active Ceased
- 2002-05-29 DK DK02731063T patent/DK1397366T3/da active
- 2002-05-29 IL IL15873502A patent/IL158735A0/xx unknown
- 2002-05-29 PT PT02731063T patent/PT1397366E/pt unknown
- 2002-05-29 SI SI200230510T patent/SI1397366T1/sl unknown
- 2002-05-29 NZ NZ529426A patent/NZ529426A/en unknown
- 2002-05-29 CA CA002455341A patent/CA2455341A1/en not_active Abandoned
- 2002-05-29 MX MXPA03010996A patent/MXPA03010996A/es active IP Right Grant
- 2002-05-29 JP JP2003500091A patent/JP2004532877A/ja active Pending
- 2002-05-29 ES ES02731063T patent/ES2280538T3/es not_active Expired - Lifetime
- 2002-05-29 EP EP02731063A patent/EP1397366B1/en not_active Expired - Lifetime
- 2002-05-29 CN CNB028110498A patent/CN1294136C/zh not_active Expired - Fee Related
- 2002-05-29 DE DE60218032T patent/DE60218032T2/de not_active Expired - Fee Related
- 2002-05-29 AT AT02731063T patent/ATE353332T1/de not_active IP Right Cessation
- 2002-05-29 BR BR0210075-4A patent/BR0210075A/pt not_active IP Right Cessation
- 2002-05-29 KR KR10-2003-7015462A patent/KR20040003021A/ko not_active Ceased
-
2003
- 2003-11-11 ZA ZA200308779A patent/ZA200308779B/en unknown
- 2003-11-28 NO NO20035333A patent/NO20035333D0/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4279070B1 (en) | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine | |
| JP2003512374A5 (enExample) | ||
| JP2003514818A5 (enExample) | ||
| JP2003513073A5 (enExample) | ||
| PH12019500004A1 (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| TWI248932B (en) | Respiratory syncytial virus replication inhibitors | |
| JP2003513071A5 (enExample) | ||
| JP2020514318A5 (enExample) | ||
| TWI657078B (zh) | 作爲單胺氧化酶（ｍａｏ）抑制劑之經取代之萘啶及喹啉化合物 | |
| JP2007532637A5 (enExample) | ||
| Mazurov et al. | 2-(Arylmethyl)-3-substituted quinuclidines as selective α7 nicotinic receptor ligands | |
| NZ592961A (en) | Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators | |
| JP2001510194A5 (enExample) | ||
| AU2022413759A1 (en) | Benzoate salt of 5-methoxy-n,n-dimethyltryptamine | |
| JP2005534624A5 (enExample) | ||
| JP2009537517A5 (enExample) | ||
| JP2010511668A5 (enExample) | ||
| US20210171497A1 (en) | Eaat2 activators and methods of using thereof | |
| JP2022539152A5 (enExample) | ||
| JP2022549335A5 (enExample) | ||
| JP2019534327A5 (enExample) | ||
| JP2019512469A5 (enExample) | ||
| JP2005500354A5 (enExample) | ||
| WO2019220138A1 (en) | Ketamine derivatives to treat neurological or psychological diseases | |
| RU2006125636A (ru) | Лиганды никотиновых рецепторов ацетилхолина |